InterCure Continuing its Medical Cannabis Consolidation Strategy, Announces Strategic Acquisition of Cannomed Pharmacy Chain

InterCure继续其医用大麻整合战略,宣布战略收购Cannomed药房连锁店

2021-09-03 10:00:12 CFN Media Group

本文共1975个字,阅读需5分钟

Acquisition includes two medical cannabis dispensing pharmacies, another pharmacy in the process of receiving its license and a medical cannabis patient support center. Companies will partner in Cannomed online platform dedicated to fulfilling orders of medical cannabis products and in medical cannabis cultivation and importation   NEW YORK, TORONTO, and HERZLIYA, Israel, Sept. 02, 2021 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) today announced that it has signed an agreement in which InterCure will purchase strategic assets from Cannomed (TASE: CNMD), an Israel-based company and owner of a pharmacy chain specializing in dispensing medical cannabis.   According to the agreement, the Company will acquire Cannomed’s holdings; 55% of ‘Max Pharm’ (which operates two medical cannabis dispensing pharmacies), 100% of a pharmacy in the process of receiving its license and 51% of ‘Hello Pharm’ a medical cannabis patient support center. The companies will partner in Cannomed innovative e-commerce platform for medical cannabis products. InterCure’s medical pharmacy chain, ‘GIVOL’, will onboard this new platform throughout its various locations, adding a complementary e-commerce operation to GIVOL’s extensive retail footprint. The online platform is expected to go live, pending approvals from applicable Israeli regulatory authorities.   The acquisition expands InterCure’s sales and distribution channels in response to the growing demand for its branded products and the consistent increase in the number of medical cannabis patients in Israel, currently estimated at a growth rate of 4%1 per month.   Cannomed was one of the first Israeli companies to acquire Israeli Medical Cannabis Agency (IMCA) approved pharmacies to meet the growing demand by patients. The acquisition of its dispensing operation is part of InterCure’s growth strategy to further improve sales and profitability, as the Company continues to execute on its consolidation strategy of the Israeli medical cannabis market, which began with its previously announced acquisition of Israeli licensed cannabis producer ‘Better’.   The two companies will also reach a medical cannabis cultivation and importation agreement, in which Cannomed supply medical cannabis for the Company.   “Intercure is further capitalizing on its growth momentum, which is supporting our move of leading the consolidation of the medical cannabis market,” said InterCure CFO, Amos Cohen. “This transaction with Cannomed is another step in the implementation of our strategy and strengthens InterCure’s position.”   About InterCure (dba Canndoc) InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to maintain its position as Israel’s leading cannabis company as well as to drive further growth through global expansion.   For more information, visit: http://www.intercure.co   Forward-Looking Statements This press release may contain forward-looking information within the meaning of applicable securities legislation, which reflects InterCure’s current expectations regarding future events. The words “will”, “expects”, “intends” and similar expressions are often intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Specific forward-looking information contained in this press release includes, but is not limited to: the success of the acquisition of Cannomed assets and the future outcomes of such acquisition, the success of the future partnership between the Company and Cannomed, the Company’s future revenue growth and results, the success of its global expansion plans, its continued growth, the expected operations, financial results, business strategy, competitive strengths, goals and expansion and growth plans and the expansion strategy to major markets worldwide. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond InterCure’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to: changes in general economic, business and political conditions, changes in applicable laws, the Canadian regulatory landscapes and enforcement related to cannabis, changes in public opinion and perception of the cannabis industry, reliance on the expertise and judgment of senior management, as well as the factors discussed under the heading “Risk Factors” ” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form 20-F, filed with the Securities Exchange Commission on August 16, 2021. InterCure undertakes no obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Contact: InterCure Ltd. Amos Cohen, Chief Financial Officer [email protected] KCSA Strategic Communications Investor and Media Relations [email protected] This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
收购包括两家医用大麻配药药店、另一家正在领取许可证的药店和一个医用大麻患者支持中心。 公司将与Cannomed在线平台合作,致力于实现医用大麻产品的订单,并在医用大麻种植和进口方面合作 2021年9月2日,纽约、多伦多和以色列赫兹利亚(环球新闻)--InterCure Ltd.(Nasdaq:INCR)(TSX:INCR.U)(TASE:INCR)(dba Canndoc)(“InterCure”或“公司”)今天宣布,它已经签署了一项协议,InterCure将从Cannomed(TASE:CNMD)购买战略资产,Cannomed是一家总部位于以色列的公司,也是一家专门从事医用大麻配药的连锁药店的所有者。 根据协议,公司将收购Cannomed的控股;55%的“Max Pharm”(经营两家医用大麻配药药店)、100%的正在领取许可证的药店和51%的“Hello Pharm”医用大麻患者支持中心。两家公司将在Cannomed创新的医用大麻产品电子商务平台上合作。Intercure的医疗药房连锁店“Givol”将在其不同的位置上使用这个新平台,为Givol广泛的零售足迹增加一个互补的电子商务业务。该在线平台预计将上线,等待以色列相关监管机构的批准。 收购扩大了Intercure的销售和分销渠道,以应对对其品牌产品的日益增长的需求以及以色列医用大麻患者数量的持续增长,目前估计增长率为每月4%1。 Cannemed是第一批收购以色列医用大麻机构(IMCA)批准的药店以满足患者日益增长的需求的以色列公司之一。收购其配药业务是Intercure进一步提高销售和盈利能力的增长战略的一部分,因为该公司继续执行其以色列医用大麻市场的整合战略,该战略始于其此前宣布的收购以色列特许大麻生产商“Better”。 两家公司还将达成医用大麻种植和进口协议,Cannomed为该公司供应医用大麻。 InterCure首席财务官阿莫斯·科恩(Amos Cohen)表示:“InterCure正在进一步利用其增长势头,这支持我们领导医用大麻市场整合的举措。”“与Cannomed的这笔交易是我们实施战略的又一步,并加强了Intercure的地位。” 关于InterCure(dba Canndoc) InterCure(dba Canndoc)(Nasdaq:INCR)(TSX:INCR.U)(TASE:INCR)是北美以外领先的大麻公司。Canndoc是InterCure的全资子公司,是以色列最大的许可大麻生产商,也是首批提供经良好生产规范(GMP)认证的药品级医用大麻产品的生产商之一。InterCure利用其市场领先的分销网络、一流的国际合作伙伴关系和高利润的垂直一体化“从种子到销售”模式,保持其作为以色列领先大麻公司的地位,并通过全球扩张推动进一步增长。 欲了解更多信息,请访问:http://www.intercure.co 前瞻性陈述 本新闻稿可能包含适用证券立法含义内的前瞻性信息,反映了Intercure对未来事件的当前预期。“将”、“预期”、“打算”等词和类似的表达方式通常是为了识别前瞻性信息,尽管并非所有前瞻性信息都包含这些识别词。本新闻稿所载的具体前瞻性信息包括但不限于:收购Cannomed资产的成功及收购的未来结果、本公司与Cannomed未来伙伴关系的成功、本公司未来收入增长及业绩、其全球扩张计划的成功、其持续增长、预期运营、财务业绩、业务战略、竞争优势、目标、扩张及增长计划以及向全球主要市场的扩张战略。前瞻性信息基于多项假设,并受制于多项风险和不确定性,其中许多风险和不确定性是Intercure无法控制的,可能导致实际结果和事件与该等前瞻性信息中披露或暗示的结果和事件大不相同。该等风险及不确定因素包括但不限于:一般经济、商业及政治状况的变化,适用法律的变化,加拿大与大麻有关的监管环境及执法,公众舆论及对大麻行业看法的变化,对高级管理层专业知识及判断的依赖,以及于2021年8月16日向证券交易委员会提交的表格20-F注册声明中“风险因素”及“有关前瞻性陈述的警告性说明”标题下讨论的因素。除适用法律明确要求外,InterCure不承担任何义务更新该前瞻性信息,无论是由于新信息、未来事件或其他原因。 联系人: InterCure有限公司。 阿莫斯·科恩,首席财务官 [电子邮件受保护] 战略传播 投资者与媒体关系 [电子邮件受保护] 本文由CFN Enterprises Inc.(OTCQB:CNFN)发表,该公司是CFN Media的所有者和运营商,CFN Media是行业领先的机构和数字金融媒体网络,致力于新兴的CBD和合法大麻行业。请致电+1(833)420-CNFN了解更多信息。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文